Active Biotech enters agreement for a clinical study of tasquinimod in myelofibrosis
Lund, July 1, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into a clinical study agreement for a Phase II investigator-initiated clinical study investigating the use of tasquinimod in myelofibrosis. The study will be led by Lucia Masarova, M.D., assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. Active Biotech will support the study with the Investigational Medicinal Product and related costs.
The clinical study, entitled Open Label Phase 2 Study of Tasquinimod in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF), will evaluate the efficacy and safety of tasquinimod in patients with myelofibrosis.
The primary objective of the study is to determine the anti-tumor activity of tasquinimod as monotherapy and in combination with a stable dose of ruxolitinib based on the measurement of objective response rate (ORR) after six cycles of treatment. Secondary objectives include safety and tolerability, symptom burden, duration of response and bone marrow fibrosis grade.
More information about the study is available at ClinicalTrials.gov NCT06327100.
“This is the first time tasquinimod will be evaluated in patients with myelofibrosis. With a well-known safety profile from previous clinical studies and strong preclinical myelofibrosis data, we will now test the hypothesis that tasquinimod can act as a disease modifying treatment in this group of patients with a high unmet medical need. At present, JAK inhibitors is the only approved drug class in myelofibrosis, and there is an urgent need for effective and safe compounds with a new mechanism of action,” said Erik Vahtola, Chief Medical Officer at Active Biotech.